Table 1.
Baseline characteristics of patients who underwent an acute surgical intervention for esophageal cancer in the Netherlands between 2011 and 2017
| Characteristics | All | |
|---|---|---|
| n = 17 | % | |
| Patient-related characteristics | ||
| Age, years (mean ± SD) | 64 ± 11 | |
| Sex | ||
| Male | 15 | 88% |
| Female | 2 | 12% |
| BMI, kg/m2 (mean ± SD) | 26 ± 5 | |
| ASA classification | ||
| I | 2 | 12% |
| II | 7 | 41% |
| III | 7 | 41% |
| IV | 1 | 6% |
| Comorbidities | ||
| Cardiac | 2 | 12% |
| Vascular | 8 | 47% |
| Diabetes | 5 | 29% |
| Pulmonary | 3 | 18% |
| Previous abdominal or thoracic surgery | 7 | 41% |
| Tumor location | ||
| Middle esophagus | 1 | 6% |
| Distal esophagus | 9 | 53% |
| Gastro-esophageal junction | 5 | 29% |
| Unknown | 2 | 12% |
| Histology | ||
| Adenocarcinoma | 15 | 88% |
| Squamous cell carcinoma | 1 | 6% |
| Other | 1 | 6% |
| cT statusa | ||
| T1 | 3 | 18% |
| T2 | 2 | 12% |
| T3 | 5 | 29% |
| T4 | 5 | 29% |
| Tx | 2 | 12% |
| cN statusa | ||
| N0 | 6 | 35% |
| N+ | 8 | 47% |
| Nx | 3 | 18% |
| cM statusa | ||
| M0 | 13 | 76% |
| M1 | 2 | 12% |
| Mx | 2 | 12% |
| Treatment-related characteristics | ||
| Neoadjuvant therapyb | ||
| None | 10 | 59% |
| Chemoradiotherapy | 4 | 24% |
| Chemotherapy | 2 | 12% |
| Radiotherapy | 1 | 6% |
| Setting | ||
| Emergent (< 12 h) | 10 | 59% |
| Urgent (> 12 h) | 8 | 41% |
| Reason for emergency surgery | ||
| Bleeding | 5 | 29% |
| Perforation | 7 | 41% |
| Other/unknown | 5 | 29% |
| Surgical approach | ||
| Minimally invasive | 9 | 53% |
| Open | 8 | 47% |
| Surgical procedure | ||
| Transhiatal esophagectomy | 9 | 53% |
| Transthoracic esophagectomy | 5 | 29% |
| Diagnostic thoracotomy | 1 | 6% |
| Diagnostic laparoscopy | 2 | 12% |
| Reconstruction | ||
| Gastric conduit reconstruction | 12 | 71% |
| No reconstruction | 4 | 24% |
| Unknown | 1 | 6% |
| Location of anastomosis | ||
| Cervical | 10 | 59% |
| Intrathoracic | 2 | 12% |
| Not applicable | 5 | 29% |
| Lymph node dissection | 13 | 76% |
| Year of surgery | ||
| 2011–2013 | 9 | 53% |
| 2014–2017 | 8 | 47% |
Data are numbers of patients with column-based percentages in parentheses, unless otherwise stated
ASA American Society of Anesthesiologists; BMI body mass index at diagnosis; SD standard deviation
aClinical T status and N status are based on AJCC TNM 7th edition
bThe standard regimen for neoadjuvant treatment for esophageal cancer patients in the Netherlands consists of carboplatin and paclitaxel, weekly during 5 weeks, and concurrent radiotherapy with a total radiation dose of 41.4 Gy in 23 fractions of 1.8 Gy. For gastro-esophageal junction or gastric adenocarcinoma, peri-operative treatment generally consists of chemotherapy regimens similar to the MAGIC-trial (epirubicin, cisplatin and capecitabine)